MedTrace Logo

Combining Varenicline and Naltrexone for Smoking Cessation

NCT02698215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2021-06-15

Study results available
· View outcomes & findings →

Summary

This study is a double-blind, randomized clinical trial using a two group medication design consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1 mg twice daily) + PLA (matched to NTX), for smoking cessation in a sample of heavy drinking daily smokers who want to quit smoking and reduce drinking.

Conditions

Interventions

DRUG

Varenicline

Varenicline 1 mg twice daily

DRUG

Varenicline plus Naltrexone

Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily

Sponsors & Collaborators

Principal Investigators

  • Lara Ray, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698215 on ClinicalTrials.gov